Axa S.A. Decreases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

AXA S.A. lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 73.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,257,149 shares of the medical device company's stock after selling 6,276,332 shares during the period. AXA S.A. owned about 0.58% of DexCom worth $175,538,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of DexCom by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after acquiring an additional 56,094 shares during the period. Jennison Associates LLC increased its stake in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after purchasing an additional 710,858 shares in the last quarter. Norges Bank bought a new stake in shares of DexCom in the fourth quarter valued at approximately $385,367,000. Northern Trust Corp lifted its stake in shares of DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after buying an additional 753,857 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in DexCom by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after buying an additional 91,051 shares during the period. Institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Piper Sandler decreased their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday. Robert W. Baird lowered their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Canaccord Genuity Group increased their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and a consensus target price of $98.11.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,926 shares of company stock valued at $4,734,384. Insiders own 0.32% of the company's stock.

DexCom Stock Down 1.7 %

DXCM stock traded down $1.35 during trading on Monday, hitting $80.27. 5,371,321 shares of the company's stock traded hands, compared to its average volume of 4,270,825. The business has a fifty day simple moving average of $71.27 and a two-hundred day simple moving average of $76.93. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $31.47 billion, a P/E ratio of 56.13, a PEG ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the business posted $0.32 earnings per share. The firm's quarterly revenue was up 12.5% on a year-over-year basis. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.